300 related articles for article (PubMed ID: 16573787)
1. Systematic review: the use of mesalazine in inflammatory bowel disease.
Bergman R; Parkes M
Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
[TBL] [Abstract][Full Text] [Related]
2. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
3. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
5. A practical guide to the management of distal ulcerative colitis.
Ardizzone S; Bianchi Porro G
Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
[TBL] [Abstract][Full Text] [Related]
6. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
7. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
8. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
[TBL] [Abstract][Full Text] [Related]
9. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
[TBL] [Abstract][Full Text] [Related]
10. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
Thomson AB
Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
12. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
13. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Safdi AV; Cohen RD
Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine in childhood inflammatory bowel disease.
Barden L; Lipson A; Pert P; Walker-Smith JA
Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
[TBL] [Abstract][Full Text] [Related]
16. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine].
Martínez González J; Busto Bea V; Mesonero Gismero F; Parejo Carbonell S; Garrido E; López San Román A
Gastroenterol Hepatol; 2013 Jan; 36(1):7-10. PubMed ID: 23195755
[TBL] [Abstract][Full Text] [Related]
17. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
18. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
19. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis.
Barberio B; Segal JP; Quraishi MN; Black CJ; Savarino EV; Ford AC
J Crohns Colitis; 2021 Jul; 15(7):1184-1196. PubMed ID: 33433562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
